Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs

IMPORTANCE: In many health systems, access to off-label drug use is controlled through reimbursement restrictions by health insurers, especially for expensive cancer drugs. OBJECTIVE: To determine whether evidence from randomized clinical trials is associated with reimbursement decisions for request...

Descripción completa

Detalles Bibliográficos
Autores principales: Herbrand, Amanda Katherina, Schmitt, Andreas M., Briel, Matthias, Ewald, Hannah, Goldkuhle, Marius, Diem, Stefan, Hoogkamer, Anouk, Joerger, Markus, Moffa, Giusi, Novak, Urban, Hemkens, Lars G., Kasenda, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926292/
https://www.ncbi.nlm.nih.gov/pubmed/33651108
http://dx.doi.org/10.1001/jamanetworkopen.2021.0380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926292/
https://www.ncbi.nlm.nih.gov/pubmed/33651108
http://dx.doi.org/10.1001/jamanetworkopen.2021.0380

Ejemplares similares